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M ale gender is associated with a higher morbidityand mortality in both children and adolescents
with chronic kidney disease (CKD).1 Testosterone has
been implicated in the difference of progression of CKD,
by gender.2 Children with renal dysplasia often reach
end-stage kidney disease during puberty.3,4 There is ev-
idence for a signiﬁcantly steeper deterioration of renal
functionduringpuberty, independent of changes inbody
composition.3 In adults, there is also evidence for gender
disparity of progression of CKD,5 with a higher rate of
end-stage kidney disease in men.5 The direct inﬂuence of
testosterone upon renal function, and in particular renal
hemodynamics, has not been established in humans.
We recently had the opportunity to observe substan-
tial worsening of renal function in a 14-year-old boywith
hypergonadotropic hypogonadism who had repeatedly
exhibited reduction in renal function following admin-
istration of testosterone. We used a novel computed to-
mography (CT) perfusion imaging technique. This was
combined with a state-of-the-art 256-slice CT scanner, to
provide whole organ coverage without the challenges of
image registration associated with the limited scan slice
thickness of commonly available instruments. This
allowed an in vivo assessment of renal blood ﬂow, pat-
terns of renal perfusion, and other functional parameters
of the kidneys in previously unobtainable detail. Our
method has not been published, but the principles of
measuring renal blood ﬂow and blood volume are com-
parable to those presented by Ehling et al.6
CASE PRESENTATION
A 14-year-old boy with Townes Brock syndrome
(Online Mendelian Inheritance in Man #107480) and
CKD stage 3 (estimated glomerular ﬁltration rate [eGFR],
33 ml/min per 1.73 m2 based on cystatin C,7 [pediatriccystatin C eGFR reference interval, 90–135 mL/min per
1.73m2]) and cryptorchidism was treated with 3
monthly 50-mg depot testosterone i.m. injections to
promote pubertal development. Before these injections,
his luteinizing hormone was pubertal at 13.4 IU/l
(reference range, 1.7–8.6 IU/l) and follicle-stimulating
hormone was 8.0 IU/l (reference range, 1.5–12.4 IU/l].
His testosterone concentration was inappropriately low
at 3.4 nmol/l (reference interval, 8.6–29.0 nmol/l),
consistent with hypergonadotropic hypogonadism.
Full informed written consent was obtained from the
consenting minor and his caregiver.
Following the injections, the patient’s serum
creatinine levels increased from 133 to 211 mmol/l
(reference interval, 62–120 mmol/l) and cystatin C
increased from 2.5 to 3.5 mg/l (reference interval,
0.27–1.20 mg/l). The cystatin C eGFR7 dropped to 22
ml/min per 1.73 m2. For consistency, all eGFR mea-
surements reported here are based on the cystatin
C eGFR. The boy’s height was 169.2 cm (50th
percentile) and his weight was 113.8 kg (> 99th
percentile). His medication at that time included 10
mg ramipril twice daily, 25 mg carvedilol twice daily,
20 mg hydralazine thrice daily, 12.5 mg hydrochlo-
rothiazide once daily, 1000 U vitamin D and 25 mg
alfacalcidol at bedtime, 4000 mg sodium bicarbonate
thrice daily, and ferrous sulfate 300 mg at lunchtime
and 20 mg darbepoetin alfa every 4 weeks subcuta-
neously. Blood pressure was 131/71 mm Hg. His
medication remained unchanged except for a need for
a higher darbepoietin dosage, which was changed to
every fortnight. Blood pressure improved slightly to
122/68 mm Hg.
After cessation of testosterone, the patient’s serum
creatinine level dropped to 140 mmol/l and his cystatin
C level dropped to 2.3 mg/l. He remained stable at this
level of kidney function for 6 months, when he wasKidney International Reports (2016) 1, 306–310
Table 2. Renal perfusion before and after testosterone exposure
Exposure
Blood
ﬂow
Blood
volume
Mean
transit
time
Permeability
surface area
product
Contrast
appearance
time
Before testosterone
Slice 1 252.67 27.458 7.69 50.822 0.653
Slice 2 261.96 26.976 7.12 52.875 0.842
Slice 3 244.34 27.352 7.62 53.836 0.66
Slice 4 246 27.661 7.47 58.322 0.636
Slice 5 263.56 27.188 7.06 57.231 0.72
G Filler et al.: Is Testosterone Detrimental to Renal Function? NEPHROLOGY ROUNDSrechallenged with a single dose of 50 mg testosterone
i.m. for continued cryptorchidism and hypogonadism.
Again, his serum creatinine level rose to 206 mmol/l and
cystatin C to 2.95 mg/l, which equated to an eGFR of 27
ml/min per 1.73 m2. The changes induced by the
testosterone challenge are given in Table 1. Magne-
sium, glucose, white blood cell count, platelets, thyroid
stimulating hormone, and vitamin D metabolite levels
were unchanged.
To further establish a potential direct causal link
between testosterone exposure and to inform clinical
choices over future sex hormone supplementation in
this patient, CT perfusion imaging was performed
before and after rechallenging with testosterone. Im-
aging was done on a GE Revolution 256-slice CT scanner
(Boston, MA, USA) at St Joseph’s Health Care London,
Ontario, Canada. Following low-volume iodinated
contrast agent injection, dynamic contrast enhanced CT
scanning of a 16-cm section of the abdomen fully
encompassing both kidneys was performed without
breath-hold. The section was divided into 32 slices of 5-
mm thickness each and was scanned 42 times at 2.8-
second intervals using 120 kV and 22.4 mA for a
duration of approximately 2 minutes. Following the
scan, images were reconstructed using adaptive statis-
tical iterative reconstruction (GE Health Care Canada
Inc, Mississauga, ON) to reduce image noise.
CT images were registered using nonrigid registra-
tion to minimize the effects of breathing motion during
scanning. Registered images were analyzed using pro-
totype CT Perfusion 4D software (GE Healthcare).
Following artery region of interest selection, functional
maps were computed for blood ﬂow (BF), blood vol-
ume, mean transit time (a marker of blood ﬂow over
time), permeability surface area product, and contrast
appearance time. Next, regions of interest were drawn
over the kidney in the BF maps to encompass medullarTable 1. Clinical laboratory markers before and after the
testosterone rechallenge
Parameter
Reference
interval Pretestosterone
1 month
posttestosterone
Sodium (mmol/l) 135-145 139 140
Potassium (mmol/l) 3.5-5.0 4.7 4.2
Chloride (mmol/l) 98-107 104 101
Bicarbonate (mmol/l) 22-29 20 25
Urea (mmol/l) < 8.0 10.7 13.6
Creatinine (mmol/l) 62-120 122 206
Calcium (mmol/l) 2.15-2.55 2.24 2.31
Phosphate (mmol/l) 0.8-1.33 1.14 1.37
Hemoglobin (g/l) 125-160 139 116
Parathyroid hormone (pmol/l) 1.6-6.9 8.0 12.0
Aldosterone (pmol/l) < 729 < 83 < 83
Microalbumin/creatinine
(mg/mmol)
0.0-2.0 50.9 17.6
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the selected transverse slices to determine mean kidney
BF values.
The testosterone re-exposure (measured 2 weeks after
the re-exposure), and reduction in renal function, was
associated with an 11% reduction in cortical
BF. Average cortical BF dropped from 242 mL/min per
100 g to 216 mL/min per 100 g (P ¼ 0.01, paired t test)
(Table 2). Mean transit time decreased from 7.8 to 9.6
seconds (P ¼ 0.00028). Blood volume and permeability
surface area product remained unchanged. Medullary
BF was relatively preserved compared with cortical BF
(see Figure 1). Furthermore, the reduction in tissue
perfusion was markedly heterogeneous (see Table 2),
consistent with microcirculatory dysfunction.8 The pa-
tient received only 1 dose of testosterone but the cys-
tatin C and serum creatinine did not fully recover after
the re-exposure to testosterone. With the re-exposure,
the patient’s serum creatinine level increased to 473
mmol/l 1 month after the injection and only recovered to
254 mmol/l, and cystatin C peaked at 5.35 mg/l and
dropped only down to 4.16 mg/l. He subsequently un-
derwent bilateral inguinal orchidopexy.
DISCUSSION
We present a case of acute testosterone-induced dete-
rioration of renal function in a 14-year-old boy withSlice 6 241 28.803 7.84 57.483 0.551
Slice 7 221.89 27.866 7.86 54.375 0.575
Slice 8 221.9 29.533 8.43 52.172 0.518
Slice 9 227.18 32.276 9.02 52.724 0.394
Mean 242.28 28.35 7.79 54.43 0.62
SD 15.92 1.69 0.62 2.65 0.13
After testosterone
Slice 1 201.47 30.229 10.265 80.764 0.218
Slice 2 206.09 28.802 9.75 68.982 0.397
Slice 3 211.77 26.746 8.31 67.002 0.459
Slice 4 231.15 27.097 8.75 64.737 0.45
Slice 5 252.31 27.583 8.31 67.618 0.524
Slice 6 253.44 27.824 8.36 62.308 0.585
Slice 7 226.71 29.91 9.97 51.273 0.454
Slice 8 184.47 34.209 11.239 42.549 0.24
Slice 9 181.56 34.426 11.506 41.177 0.204
Mean 216.55 29.65 9.61 60.71 0.39
SD 26.38 2.90 1.25 13.12 0.14
Paired t test 0.01395 0.07131 0.00028 0.18923 0.00196
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Figure 1. Representative ﬁgures from computed tomography perfusion imaging (a and c) and corresponding blood ﬂow maps (b and d) with
regions of interest drawn over the medulla (green) and cortex (magenta) before (a and b) and after (c and d) testosterone.
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hypogonadism. Further reduction of renal function
after subsequent reintroduction of testosterone was
associated with the same response, inferring an asso-
ciation. The pathophysiology of this effect appears to
be attributable to testosterone-mediated changes in
intrarenal hemodynamic parameters. This was
conﬁrmed on direct dynamic imaging and strongly
supported by the observed reduction in proteinuria.
The key questions raised by this potentially highly
instructive case are, Why did this happen? and, Why
was it reversible? There are several reports about a
differential effect of sex hormones on renal tissues,
including differential effects on mesangial cell prolif-
eration,9 collagen synthesis,9,10 and apoptosis.11,12
Animal data suggest that podocytes are a target for308testosterone. Testosterone has been shown to induce
podocyte damage and apoptosis, whereas 17-b estradiol
was protective.10 However, low-dose testosterone has
been found to be protective against renal ischemia-
reperfusion injury,13,14 and a recent study found an
association with low testosterone levels and lower eGFR
in a cross-sectional study of men aged 40 to 80 years.15
In our case, the effect of testosterone was reversible
because renal function returned to normal following
cessation of testosterone replacement therapy, at least
the ﬁrst time. However, renal function did not return
to baseline after re-exposure. There is evidence for the
presence of testosterone receptors on the afferent
arteriole of the kidneys and a speciﬁc dose-dependent
effect of testosterone in an arteriole culture model.16
Afferent arterioles are the major resistance vessels inKidney International Reports (2016) 1, 306–310
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opment of renal injury and hypertension. The revers-
ible worsening of renal function, decrease of renal
blood ﬂow, and reduction of proteinuria suggest that
changes in the renal perfusion rather than permanent
damage to the nephrons were responsible for the
observed effect. Furthermore, this implies that testos-
terone may be a key contributor to the observed
gender differences in CKD progression and the devel-
opment of acute kidney injury. Detailed intrarenal
perfusion studies in animal models of acute kidney
injury consistently identify the importance of the
heterogeneity of perfusion within the organ.17–19 This
pattern of perfusion was present within the kidneys of
this patient after testosterone challenge. Such detailed
study of these effects have not been previously
possible to examine in humans, due to imaging tech-
nology limitations.
A strength of our case report is the fact that renal
function was measured using both cystatin C and
creatinine, thereby excluding the likelihood that
changes in the tubular secretion of creatinine were
responsible for the observed increase in renal retention
parameters.20 The weight of the patient did not change,
making changes in muscle mass unlikely. Another
strength lies is the objective conﬁrmation of renal
perfusion changes by taking advantage of cutting-edge
developments in both imaging technology and
sequence development. There are several limitations,
mostly due to the fact that a single case is presented
without conﬁrming the effects in other subjects, and the
fact that a therapeutic testosterone dose was adminis-
tered for the purpose of inducing puberty in a single
dose rather than gradually increasing testosterone
concentrations. Physiological changes of testosterone
during puberty may have a much more blunted effect.
It is also unclear if a sustained exposure to testosterone
may have irreversible effects. It was fortuitous that
with the particular circumstances in this patient, and
the availability of renal perfusion measurement, we
were able to establish an association and a possible
pathomechanism for the observed testosterone-induced
renal dysfunction. However, although the amount of
contrast was very small, contrast-related acute kidney
injury could have confounded the effect of testosterone,
although serum creatinine and cystatin C levels were
unaffected by the ﬁrst contrast study.
This patient represents an index case to establish the
importance of sex hormone status within the setting of
CKD. This study provides the ﬁrst direct human
experimental evidence that testosterone directly mod-
ulates renal perfusion. This may be of crucial impor-
tance in understanding the observed sex differences in
vulnerability to CKD and suggests that this may be anKidney International Reports (2016) 1, 306–310important dimension to be considered in future
research into the development and progression of CKD.
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